Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Weibo Corp (WB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Weibo Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Weibo Corp trades at $7.66 (market cap $1.85B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.4× Weibo Corp's market cap, and Weibo Corp pays a 8.16% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WB | |
|---|---|---|
Market Cap | $4.49B | $1.85B |
Sector | Health | Media |
52-Week High | $28.06 | $12.83 |
52-Week Low | $20.06 | $7.20 |
Enterprise Value | $3.69B | $1.12B |
Dividend Yield | — | 8.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Weibo (WB) trades at $7.47, up 1.49% today, with a bullish technical signal and strong fundamentals including a 25.55% net margin and 10.33% ROE. Recent quarterly earnings missed expectations, but the company maintains robust cash flow and a high dividend yield. Valuation metrics appear attractive with a P/E of 5.29 and P/B of 0.48, while analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. The stock offers significant upside if monetization improves, but faces risks from user engagement declines and rivalry with Douyin. Near-term catalysts include Q2 2026 earnings and dividend payments, though consistent EPS misses warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
